Role of collagenase clostridium histolyticum in Peyronie’s disease

Peyronie’s disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie’s disease include D...

Descripción completa

Detalles Bibliográficos
Autores principales: Peak, Taylor C, Mitchell, Gregory C, Yafi, Faysal A, Hellstrom, Wayne J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598203/
https://www.ncbi.nlm.nih.gov/pubmed/26491251
http://dx.doi.org/10.2147/BTT.S65619
_version_ 1782394052224745472
author Peak, Taylor C
Mitchell, Gregory C
Yafi, Faysal A
Hellstrom, Wayne J
author_facet Peak, Taylor C
Mitchell, Gregory C
Yafi, Faysal A
Hellstrom, Wayne J
author_sort Peak, Taylor C
collection PubMed
description Peyronie’s disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie’s disease include Dupuytren’s contracture, penile trauma, and family history. A variety of treatment strategies have been utilized, including oral and topical agents, electromotive drug administration, intralesional injections, extracorporeal shockwave therapy, penile traction, and surgery. However, most of these strategies are ineffective, with surgery being the only definitive treatment. Collagenase clostridium histolyticum is a newly US Food and Drug Administration-approved agent for intralesional injection. It is thought to downregulate many of the disease-related genes, cytokines, and growth factors and degrade collagen fibers. It also suppresses cell attachment, spreading, and proliferation. Collagenase clostridium histolyticum has been clinically proven to be a safe and effective therapeutic option, demonstrating decreases in penile curvature and plaque consistency, as well as increases in patient satisfaction. During clinical evaluation, the Peyronie’s Disease Questionnaire was validated as an effective tool for assessing treatment outcomes.
format Online
Article
Text
id pubmed-4598203
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45982032015-10-21 Role of collagenase clostridium histolyticum in Peyronie’s disease Peak, Taylor C Mitchell, Gregory C Yafi, Faysal A Hellstrom, Wayne J Biologics Review Peyronie’s disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie’s disease include Dupuytren’s contracture, penile trauma, and family history. A variety of treatment strategies have been utilized, including oral and topical agents, electromotive drug administration, intralesional injections, extracorporeal shockwave therapy, penile traction, and surgery. However, most of these strategies are ineffective, with surgery being the only definitive treatment. Collagenase clostridium histolyticum is a newly US Food and Drug Administration-approved agent for intralesional injection. It is thought to downregulate many of the disease-related genes, cytokines, and growth factors and degrade collagen fibers. It also suppresses cell attachment, spreading, and proliferation. Collagenase clostridium histolyticum has been clinically proven to be a safe and effective therapeutic option, demonstrating decreases in penile curvature and plaque consistency, as well as increases in patient satisfaction. During clinical evaluation, the Peyronie’s Disease Questionnaire was validated as an effective tool for assessing treatment outcomes. Dove Medical Press 2015-09-29 /pmc/articles/PMC4598203/ /pubmed/26491251 http://dx.doi.org/10.2147/BTT.S65619 Text en © 2015 Peak et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Peak, Taylor C
Mitchell, Gregory C
Yafi, Faysal A
Hellstrom, Wayne J
Role of collagenase clostridium histolyticum in Peyronie’s disease
title Role of collagenase clostridium histolyticum in Peyronie’s disease
title_full Role of collagenase clostridium histolyticum in Peyronie’s disease
title_fullStr Role of collagenase clostridium histolyticum in Peyronie’s disease
title_full_unstemmed Role of collagenase clostridium histolyticum in Peyronie’s disease
title_short Role of collagenase clostridium histolyticum in Peyronie’s disease
title_sort role of collagenase clostridium histolyticum in peyronie’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598203/
https://www.ncbi.nlm.nih.gov/pubmed/26491251
http://dx.doi.org/10.2147/BTT.S65619
work_keys_str_mv AT peaktaylorc roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease
AT mitchellgregoryc roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease
AT yafifaysala roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease
AT hellstromwaynej roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease